MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma

Overview of attention for article published in Scientific Reports, December 2019

Altmetric Badge

Mentioned by

So far, Altmetric has seen 1 X post from an account with 73 followers.

MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma. https://t.co/hCm9QahjQg

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.